Literature DB >> 16339307

The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal.

Angelo Contarino1, Francesco Papaleo.   

Abstract

The negative affective symptoms of opiate withdrawal powerfully motivate drug-seeking behavior and may trigger relapse to heroin abuse. To date, no medications exist that effectively relieve the negative affective symptoms of opiate withdrawal. The corticotropin-releasing factor (CRF) system has been hypothesized to mediate the motivational effects of drug dependence. The CRF signal is transmitted by two distinct receptors named CRF receptor-1 (CRF1) and CRF2. Here we report that genetic disruption of CRF1 receptor pathways in mice eliminates the negative affective states of opiate withdrawal. In particular, neither CRF1 receptor heterozygous (CRF1+/-) nor homozygous (CRF1-/-) null mutant mice avoided environmental cues repeatedly paired with the early phase of opiate withdrawal. These results were not due to altered associative learning processes because CRF1+/- and CRF1-/- mice displayed reliable, conditioned place aversions to environmental cues paired with the kappa-opioid receptor agonist U-50,488H. We also examined the impact of CRF1 receptor-deficiency upon opiate withdrawal-induced dynorphin activity in the nucleus accumbens, a brain molecular mechanism thought to underlie the negative affective states of drug withdrawal. Consistent with the behavioral indices, we found that, during the early phase of opiate withdrawal, neither CRF1+/- nor CRF1-/- showed increased dynorphin mRNA levels in the nucleus accumbens. This study reveals a cardinal role for CRF/CRF1 receptor pathways in the negative affective states of opiate withdrawal and suggests therapeutic strategies for the treatment of opiate addiction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339307      PMCID: PMC1317931          DOI: 10.1073/pnas.0506999102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Drug addiction, dysregulation of reward, and allostasis.

Authors:  G F Koob; M Le Moal
Journal:  Neuropsychopharmacology       Date:  2001-02       Impact factor: 7.853

Review 2.  Molecular basis of long-term plasticity underlying addiction.

Authors:  E J Nestler
Journal:  Nat Rev Neurosci       Date:  2001-02       Impact factor: 34.870

Review 3.  Stress-axis, coping and dementia: gene-manipulation studies.

Authors:  S C Heinrichs
Journal:  Trends Pharmacol Sci       Date:  1999-08       Impact factor: 14.819

4.  Regulation of cocaine reward by CREB.

Authors:  W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

5.  Effects of single and repeated morphine administration on the prodynorphin, proenkephalin and dopamine D2 receptor gene expression in the mouse brain.

Authors:  J Turchan; W Lasoń; B Budziszewska; B Przewłocka
Journal:  Neuropeptides       Date:  1997-02       Impact factor: 3.286

6.  Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal.

Authors:  S.C. Heinrichs; F. Menzaghi; G. Schulteis; G.F. Koob; L. Stinus
Journal:  Behav Pharmacol       Date:  1995-01       Impact factor: 2.293

7.  Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.

Authors:  Luis Stinus; Martine Cador; Eric P Zorrilla; George F Koob
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

Review 8.  Pharmacological treatments for heroin and cocaine addiction.

Authors:  Wim van den Brink; Jan M van Ree
Journal:  Eur Neuropsychopharmacol       Date:  2003-12       Impact factor: 4.600

9.  Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development.

Authors:  G W Smith; J M Aubry; F Dellu; A Contarino; L M Bilezikjian; L H Gold; R Chen; Y Marchuk; C Hauser; C A Bentley; P E Sawchenko; G F Koob; W Vale; K F Lee
Journal:  Neuron       Date:  1998-06       Impact factor: 17.173

10.  Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: an in situ hybridization study.

Authors:  M Jaber; E Normand; B Bloch
Journal:  Brain Res Mol Brain Res       Date:  1995-08
View more
  53 in total

1.  CRF₂ mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats.

Authors:  Javier Navarro-Zaragoza; Cristina Núñez; Jessica Ruiz-Medina; M Luisa Laorden; Olga Valverde; M Victoria Milanés
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Increased motivation to eat in opiate-withdrawn mice.

Authors:  Khalil Rouibi; Angelo Contarino
Journal:  Psychopharmacology (Berl)       Date:  2011-12-30       Impact factor: 4.530

3.  Enhanced dendritic availability of μ-opioid receptors in inhibitory neurons of the extended amygdala in mice deficient in the corticotropin-releasing factor-1 receptor.

Authors:  Azra Jaferi; Ping Zhou; Virginia M Pickel
Journal:  Synapse       Date:  2011-01       Impact factor: 2.562

4.  Remote memories are enhanced by COMT activity through dysregulation of the endocannabinoid system in the prefrontal cortex.

Authors:  D Scheggia; E Zamberletti; N Realini; M Mereu; G Contarini; V Ferretti; F Managò; G Margiani; R Brunoro; T Rubino; M A De Luca; D Piomelli; D Parolaro; F Papaleo
Journal:  Mol Psychiatry       Date:  2017-06-20       Impact factor: 15.992

5.  Hedonic Homeostatic Dysregulation as a Driver of Drug-Seeking Behavior.

Authors:  George F Koob
Journal:  Drug Discov Today Dis Models       Date:  2008

6.  Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase mRNA expression, phosphorylation, and enzyme activity in the nucleus of the solitary tract during morphine withdrawal.

Authors:  Cristina Núñez; Anna Földes; Domingo Pérez-Flores; J Carlos García-Borrón; M Luisa Laorden; Krisztina J Kovács; M Victoria Milanés
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

Review 7.  Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Signaling and the Dark Side of Addiction.

Authors:  Olivia W Miles; Victor May; Sayamwong E Hammack
Journal:  J Mol Neurosci       Date:  2018-08-03       Impact factor: 3.444

8.  Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats.

Authors:  Thomas N Greenwell; Cindy K Funk; Pietro Cottone; Heather N Richardson; Scott A Chen; Kenner C Rice; Eric P Zorrilla; George F Koob
Journal:  Addict Biol       Date:  2009-04       Impact factor: 4.280

9.  Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal.

Authors:  Francesco Papaleo; Sandy Ghozland; Manuela Ingallinesi; Amanda J Roberts; George F Koob; Angelo Contarino
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

10.  Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria.

Authors:  Michael R Bruchas; Benjamin B Land; Megumi Aita; Mei Xu; Sabiha K Barot; Shuang Li; Charles Chavkin
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.